ReviewAmerican journal of clinical dermatology2023

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis.

Diana Bernardo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.